Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review

Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review

The COVID‐19 pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three‐quarters of COVID‐19 patients admitted to the intensive care unit, and both the clinical picture and pathologic fin...

Full description

Bibliographic Details
Main Authors: Barrett, Christopher D. (Author), Moore, Hunter B. (Author), Moore, Ernest E. (Author), McIntyre, Robert C. (Author), Moore, Peter K (Author), Burke, John (Author), Hua, Fei (Author), Apgar, Joshua (Author), Talmor, Daniel S. (Author), Sauaia, Angela (Author), Liptzin, Deborah R. (Author), Veress, Livia A. (Author), Yaffe, Michael B. (Author)
Other Authors: Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: Wiley, 2020-05-11T16:14:39Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items